HC Wainwright Issues Pessimistic Estimate for CLDX Earnings
HC Wainwright analysts have lowered their FY2025 earnings per share estimates for Celldex Therapeutics from ($3.34) to ($3.67), while maintaining a "Buy" rating and a $42.00 price target. Other analysts have varied ratings, with an average target price of $43.80. Celldex's stock performance and institutional investor activities are also highlighted.
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Analysts at HC Wainwright reduced their FY2025 earnings per share estimates for Celldex Therapeutics in a report released on Tuesday, November 11th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings of ($3.67) per share for the year, down from their prior estimate of ($3.34). HC Wainwright has a "Buy" rating and a $42.00 price objective on the stock. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Celldex Therapeutics' Q4 2025 earnings at ($1.03) EPS.
Other analysts have also recently issued reports about the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. Wells Fargo & Company lowered their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 20th. Citigroup decreased their target price on Celldex Therapeutics from $56.00 to $48.00 and set a "buy" rating on the stock in a research report on Wednesday, August 20th. Barclays dropped their price target on Celldex Therapeutics from $25.00 to $21.00 and set an "underweight" rating for the company in a research report on Tuesday. Finally, Canaccord Genuity Group restated a "buy" rating and set a $62.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $43.80.
Get Celldex Therapeutics alerts:
Check Out Our Latest Stock Analysis on CLDX
Celldex Therapeutics Price Performance
Shares of CLDX traded down $0.02 during mid-day trading on Thursday, reaching $24.23. The company's stock had a trading volume of 133,419 shares, compared to its average volume of 1,015,047. The company's 50 day moving average is $25.49 and its 200 day moving average is $22.82. The stock has a market cap of $1.61 billion, a PE ratio of -8.07 and a beta of 1.36. Celldex Therapeutics has a 12-month low of $14.40 and a 12-month high of $29.05.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.
Institutional Investors Weigh In On Celldex Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Aster Capital Management DIFC Ltd bought a new stake in Celldex Therapeutics in the third quarter valued at about $26,000. Nisa Investment Advisors LLC boosted its position in shares of Celldex Therapeutics by 171.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 881 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Celldex Therapeutics in the 3rd quarter valued at about $42,000. Russell Investments Group Ltd. raised its stake in Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 501 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Celldex Therapeutics during the 3rd quarter worth approximately $63,000.
About Celldex Therapeutics
(Get Free Report)Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Further Reading
- Five stocks we like better than Celldex Therapeutics
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive
- Pros And Cons Of Monthly Dividend Stocks
- Oklo’s Meltdown Is Over: A Robust Rebound Lies Ahead
- Market Cap Calculator: How to Calculate Market Cap
- 3 Reasons On Holding’s Sell-Off Is Over and New Highs Are Coming
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Celldex Therapeutics Right Now?
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
